Champions Oncology (CSBR) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Champions Oncology is expected to report Q1 2027 results after market close on September 10. Analysts forecast a loss of $0.01 per share and revenue of approximately $15.05 million.
• The company’s previous quarter exceeded expectations, with earnings of $0.01 per share versus a projected loss of $0.05 and revenue of $13.84 million compared with the $12.89 million consensus estimate.
• Investor sentiment remains weak: the stock has an average “Sell” rating, shares recently traded near $5.22, and institutional investors own 41.3% of the company.

Champions Oncology (NASDAQ:CSBR - Get Free Report) will likely be releasing its Q1 2027 results after the market closes on Thursday, September 10th. Analysts expect Champions Oncology to announce earnings of ($0.01) per share and revenue of $15.0450 million for the quarter. Investors can find conference call details on the company's upcoming Q1 2027 earning report for the latest details on the call scheduled for Thursday, September 10, 2026 at 4:30 PM ET.

Champions Oncology (NASDAQ:CSBR - Get Free Report) last announced its quarterly earnings results on Monday, July 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.06. Champions Oncology had a negative net margin of 1.87% and a negative return on equity of 27.48%. The firm had revenue of $13.84 million during the quarter, compared to analysts' expectations of $12.89 million.

Champions Oncology Price Performance

NASDAQ:CSBR opened at $5.22 on Friday. The business's 50-day moving average is $5.51 and its two-hundred day moving average is $5.84. Champions Oncology has a 12 month low of $4.83 and a 12 month high of $8.74. The firm has a market capitalization of $72.66 million, a PE ratio of -65.25 and a beta of 0.40.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Champions Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Champions Oncology currently has an average rating of "Sell".

Institutional Investors Weigh In On Champions Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in CSBR. XTX Topco Ltd acquired a new stake in shares of Champions Oncology during the 2nd quarter valued at about $103,000. Essex Investment Management Co. LLC bought a new stake in shares of Champions Oncology in the 4th quarter valued at approximately $126,000. Jane Street Group LLC acquired a new position in Champions Oncology in the first quarter worth approximately $200,000. Goldman Sachs Group Inc. acquired a new position in Champions Oncology in the first quarter worth approximately $201,000. Finally, Acadian Asset Management LLC raised its position in Champions Oncology by 28.7% during the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company's stock valued at $341,000 after acquiring an additional 8,814 shares in the last quarter. 41.30% of the stock is owned by hedge funds and other institutional investors.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source